Objective Herpes simplex virus encephalitis (HSVE) 
Introduction

Herpes simplex virus (HSV) is a human herpes virus that can cause HSV encephalitis (HSVE), the most common, serious, sporadic, viral encephalitis in humans (1). HSVE patients who do not receive antiviral treatment have an extremely high mortality rate (about 70%), and fewer than 3% of survivors return to normal function (1, 2). Of the common central nervous system (CNS) viral infections, HSVE has a disproportionately high mortality compared with encephalitis due to other viruses. The introduction of acyclovir (ACV) has dramatically improved mortality and morbidity
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Conventional predictors of poor outcome for HSVE have been reported to include the following 5 factors: age over 30 years, duration of more than 4 days from onset to the initiation of antiviral treatment, Glasgow Coma Scale (GCS) score of 6 points or less, detection of abnormal lesions on cranial computed tomography (CT) at initiation of antiviral treatment, and the detection of more than 100 copies/mL of HSV-DNA by polymerase chain reaction (PCR) in the initial cerebrospinal fluid (CSF)
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both (patients 16, 19, 22, and 23). Of these 8 patients, 2 (patients 22 and 23) of the 4 patients who received both additional treatments after initial ACV died, and 2 (patients 20 and 21) of the 3 patients with extended ACV treatment had poor outcomes (
prolonged group are also in accordance with the conventional predictors of poor outcome for HSVE (2, 4, 5 (3, (7) (8) (9) (10) (11) (12) (13) (14) (15) . In the previous studies, the frequency of relapse after HSVE ranged from 5% to 26% (8) (9) (10) (15) . According to these studies, a low initial dose of ACV has been reported to be frequently associated with HSVE relapse (9, 15) . Although the duration of the original ACV trial (2) was 10 days, most physicians currently continue therapy for 14 -21 days to reduce the risk of relapse (3, 14, 22) . A recently published clinician's guide for HSVE (22) 
